About: Management of primary skin cancer during a pandemic: Multidisciplinary recommendations

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Management of primary skin cancer during a pandemic: Multidisciplinary recommendations Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Management of primary skin cancer during a pandemic: Multidisciplinary recommendations
Creator	Perez, A Miller, Christopher Scott, F Christopher, ; Lee, Nancy Barker, A Carlos, ; Jeffrey, ; Baumann, Brian Baumann, John Brewer, Jerry Etzkorn, Jeremy Gay, Hiram Jellinek, Nathaniel Mendenhall, William Michalski, Jeff Wilson, Lynn Devlin, M Farrin, ; Macarthur, Kelly Manian, A Phillip, ; Thorstad, L Wade, ;
source	Medline; PMC
abstract	During the coronavirus disease 2019 (COVID‐19) pandemic, providers and patients must engage in shared decision making regarding the pros and cons of early versus delayed interventions for localized skin cancer. Patients at highest risk of COVID‐19 complications are older; are immunosuppressed; and have diabetes, cancer, or cardiopulmonary disease, with multiple comorbidities associated with worse outcomes. Physicians must weigh the patient's risk of COVID‐19 complications in the event of exposure against the risk of worse oncologic outcomes from delaying cancer therapy. Herein, the authors have summarized current data regarding the risk of COVID‐19 complications and mortality based on age and comorbidities and have reviewed the literature assessing how treatment delays affect oncologic outcomes. They also have provided multidisciplinary recommendations regarding the timing of local therapy for early‐stage skin cancers during this pandemic with input from experts at 11 different institutions. For patients with Merkel cell carcinoma, the authors recommend prioritizing treatment, but a short delay can be considered for patients with favorable T1 disease who are at higher risk of COVID‐19 complications. For patients with melanoma, the authors recommend delaying the treatment of patients with T0 to T1 disease for 3 months if there is no macroscopic residual disease at the time of biopsy. Treatment of tumors ≥T2 can be delayed for 3 months if the biopsy margins are negative. For patients with cutaneous squamous cell carcinoma, those with Brigham and Women's Hospital T1 to T2a disease can have their treatment delayed for 2 to 3 months unless there is rapid growth, symptomatic lesions, or the patient is immunocompromised. The treatment of tumors ≥T2b should be prioritized, but a 1‐month to 2‐month delay is unlikely to worsen disease‐specific mortality. For patients with squamous cell carcinoma in situ and basal cell carcinoma, treatment can be deferred for 3 months unless the individual is highly symptomatic.
has issue date	2020-06-01(xsd:dateTime)
bibo:doi	10.1002/cncr.32969
bibo:pmid	32478867
has license	no-cc
sha1sum (hex)	04fd94864a9b8bfb43df0758cf39f35bd28cf6f8
schema:url	https://doi.org/10.1002/cncr.32969
resource representing a document's title	Management of primary skin cancer during a pandemic: Multidisciplinary recommendations
has PubMed Central identifier	PMC7301000
has PubMed identifier	32478867
schema:publication	Cancer
resource representing a document's body	covid:04fd94864a9b8bfb43df0758cf39f35bd28cf6f8#body_text
is schema:about of	named entity 'Management' named entity 'Skin Cancer' named entity 'radiotherapy' named entity 'metastases' named entity 'coronavirus disease 2019' named entity 'malignancy' named entity 'long-term' named entity 'chronic respiratory disease' named entity 'tumor' named entity 'diabetes' named entity 'BCC' named entity 'surgical management' named entity 'cardiopulmonary disease' named entity 'clinical practice guidelines' named entity 'BCC' named entity 'biopsy' named entity 'Pfizer' named entity 'skin cancer' named entity 'skin cancer' named entity 'carcinomas' named entity 'head and neck' named entity 'dermatofibrosarcoma protuberans' named entity 'COVID-19' named entity 'radiotherapy' named entity 'Adjuvant radiotherapy' named entity 'mortality risk' named entity 'high-risk' named entity 'Immunosuppressed' named entity 'British Association of Dermatologists' named entity 'COVID-19' named entity 'NCCN' named entity 'melanomas' named entity 'comorbidities' named entity 'tumor size' named entity 'hypofractionation' named entity 'fractionation' named entity 'Brigham and Women's Hospital' named entity 'tumor' named entity 'radiation oncology' named entity 'drug therapy' named entity 'retrospective study' named entity 'senior citizens' named entity 'clinic setting' named entity 'melanoma' named entity 'tumors' named entity 'disease-free' named entity 'treatment of patients' named entity 'stage III' named entity 'advanced stage' named entity 'NCCN' named entity 'COVID-19' named entity 'radiotherapy' named entity 'MCC' named entity 'fractionation' named entity 'leiomyosarcoma' named entity 'immunosuppressed' named entity 'cutaneous' named entity 'poorly differentiated'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software